The Genotype-to-Phenotype Dilemma: How Should Laboratories Approach Discordant Susceptibility Results?


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
19 05 2021
Historique:
pubmed: 15 1 2021
medline: 10 7 2021
entrez: 14 1 2021
Statut: epublish

Résumé

Traditional culture-based methods for identification and antimicrobial susceptibility testing (AST) of bacteria take 2 to 3 days on average. Syndromic molecular diagnostic panels have revolutionized clinical microbiology laboratories as they can simultaneously identify an organism and detect some of the most significant antimicrobial resistance (AMR) genes directly from positive blood culture broth or from various specimen types (e.g., whole blood, cerebrospinal fluid, and respiratory specimens). The presence or absence of an AMR marker associated with a particular organism can be used to predict the phenotypic AST results to more rapidly guide therapy. Numerous studies have shown that genotypic susceptibility predictions by syndromic panels can improve patient outcomes. However, an important limitation of AMR marker detection to predict phenotype is the potential discrepancies that may arise upon performing phenotypic AST of the recovered organism in culture. The focus of this minireview is to address how clinical laboratories should interpret rapid molecular results from commercial platforms in relation to phenotypic AST. Stepwise approaches and solutions are provided to resolve discordant results between genotypic and phenotypic susceptibility results.

Identifiants

pubmed: 33441396
pii: JCM.00138-20
doi: 10.1128/JCM.00138-20
pmc: PMC8316082
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 American Society for Microbiology.

Références

Pharmacotherapy. 2009 Nov;29(11):1326-43
pubmed: 19857149
IDCases. 2020 May 04;20:e00781
pubmed: 32420029
J Clin Microbiol. 2020 Jun 24;58(7):
pubmed: 32376668
J Clin Microbiol. 2008 Oct;46(10):3285-90
pubmed: 18685003
Front Microbiol. 2020 Feb 21;11:256
pubmed: 32153540
Open Forum Infect Dis. 2019 Aug 2;6(8):
pubmed: 31375823
J Clin Microbiol. 2016 Jul;54(7):1789-1796
pubmed: 27098961
J Microbiol Methods. 2019 Jan;156:29-33
pubmed: 30521867
J Clin Microbiol. 2019 Oct 23;57(11):
pubmed: 31484703
PLoS Med. 2013;10(7):e1001478
pubmed: 23843749
Open Forum Infect Dis. 2019 Aug 11;6(8):ofz353
pubmed: 31401649
J Clin Microbiol. 2018 Oct 25;56(11):
pubmed: 30185510
J Glob Infect Dis. 2010 Sep;2(3):263-74
pubmed: 20927289
J Clin Microbiol. 2013 Jun;51(6):1834-40
pubmed: 23554198
J Clin Microbiol. 2018 Mar 26;56(4):
pubmed: 29305546
PLoS One. 2015 Oct 02;10(10):e0139728
pubmed: 26431434
Clin Infect Dis. 2016 Jul 1;63(1):83-8
pubmed: 27025822
J Clin Microbiol. 2009 Jan;47(1):217-9
pubmed: 19020073
Open Forum Infect Dis. 2016 Jun 20;3(3):ofw132
pubmed: 27419191
Clin Microbiol Newsl. 2018 Jun 1;40(11):87-95
pubmed: 32287688
J Clin Microbiol. 2018 Oct 25;56(11):
pubmed: 30158194
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4119-27
pubmed: 27139479
J Clin Microbiol. 2020 Jun 24;58(7):
pubmed: 32350045
Antimicrob Agents Chemother. 2008 Dec;52(12):4407-19
pubmed: 18852274
J Clin Microbiol. 2014 Jan;52(1):283-7
pubmed: 24131696
J Clin Microbiol. 2005 Sep;43(9):4541-4
pubmed: 16145104
Antimicrob Agents Chemother. 2011 Aug;55(8):3765-73
pubmed: 21636525
Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S122-33
pubmed: 25261539
J Clin Microbiol. 2005 Aug;43(8):3818-23
pubmed: 16081917
Antimicrob Agents Chemother. 2016 May 23;60(6):3832-7
pubmed: 27021332
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Arch Pathol Lab Med. 2016 Mar;140(3):267-75
pubmed: 26927722
Diagn Microbiol Infect Dis. 2016 Feb;84(2):159-64
pubmed: 26639226
Lancet Infect Dis. 2011 Aug;11(8):595-603
pubmed: 21641281
J Antimicrob Chemother. 2011 Dec;66(12):2758-62
pubmed: 21926081
J Clin Microbiol. 2011 Dec;49(12):4297-8
pubmed: 21998432
Clin Microbiol Rev. 2016 Dec 14;30(1):381-407
pubmed: 27974411
Clin Infect Dis. 2015 Oct 1;61(7):1071-80
pubmed: 26197846
J Clin Microbiol. 2020 Jun 24;58(7):
pubmed: 32350043
J Clin Microbiol. 2011 Apr;49(4):1240-4
pubmed: 21307210
Clin Infect Dis. 2009 Dec 1;49(11):1749-55
pubmed: 19857164
J Antimicrob Chemother. 2017 Nov 1;72(11):3191-3198
pubmed: 28961942
J Clin Microbiol. 2020 Feb 24;58(3):
pubmed: 31852760
J Clin Microbiol. 2008 Jan;46(1):214-9
pubmed: 17977983
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S25-34
pubmed: 16323116
Diagn Microbiol Infect Dis. 2018 Jun;91(2):144-146
pubmed: 29449043

Auteurs

Rebecca Yee (R)

Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.

Jennifer Dien Bard (J)

Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

Patricia J Simner (PJ)

Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA psimner1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH